Why Humanigen Stock Is Down Today

Why Humanigen Stock Is Down Today
Prosper Junior Bakiny, The Motley Fool
·2 min read

Shares of Humanigen (NASDAQ: HGEN) were down by 8.6% as of 12:50 p.m. EST Wednesday, after having fallen by as much as 13% earlier in the trading day. The catalyst for these losses seems to be an update the clinical-stage biopharmaceutical company delivered regarding its phase 3 clinical trial for lenzilumab in patients hospitalized with COVID-19. The phase 3 study in question originally started in late April 2020, and its primary endpoint was time to recovery for coronavirus patients.